PL2555775T3 - Kompozycje połączenia agonistów receptora adenozyny A<sub>1</sub> i inhibitorów anhydrazy węglanowej do obniżania ciśnienia wewnątrzgałkowego - Google Patents

Kompozycje połączenia agonistów receptora adenozyny A<sub>1</sub> i inhibitorów anhydrazy węglanowej do obniżania ciśnienia wewnątrzgałkowego

Info

Publication number
PL2555775T3
PL2555775T3 PL11757063T PL11757063T PL2555775T3 PL 2555775 T3 PL2555775 T3 PL 2555775T3 PL 11757063 T PL11757063 T PL 11757063T PL 11757063 T PL11757063 T PL 11757063T PL 2555775 T3 PL2555775 T3 PL 2555775T3
Authority
PL
Poland
Prior art keywords
adenosine
agonists
intraocular pressure
carbonic anhydrase
anhydrase inhibitors
Prior art date
Application number
PL11757063T
Other languages
English (en)
Inventor
Norman N. Kim
William K. Mcvicar
Thomas G. Mccauley
Original Assignee
Inotek Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corporation filed Critical Inotek Pharmaceuticals Corporation
Publication of PL2555775T3 publication Critical patent/PL2555775T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11757063T 2010-03-19 2011-03-18 Kompozycje połączenia agonistów receptora adenozyny A<sub>1</sub> i inhibitorów anhydrazy węglanowej do obniżania ciśnienia wewnątrzgałkowego PL2555775T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31572110P 2010-03-19 2010-03-19

Publications (1)

Publication Number Publication Date
PL2555775T3 true PL2555775T3 (pl) 2017-08-31

Family

ID=44649619

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11757063T PL2555775T3 (pl) 2010-03-19 2011-03-18 Kompozycje połączenia agonistów receptora adenozyny A<sub>1</sub> i inhibitorów anhydrazy węglanowej do obniżania ciśnienia wewnątrzgałkowego

Country Status (17)

Country Link
US (1) US8440639B2 (pl)
EP (1) EP2555775B1 (pl)
JP (1) JP2013522322A (pl)
CN (1) CN102933220A (pl)
CY (1) CY1118495T1 (pl)
DK (1) DK2555775T3 (pl)
ES (1) ES2613254T3 (pl)
HR (1) HRP20170008T1 (pl)
HU (1) HUE031529T2 (pl)
LT (1) LT2555775T (pl)
ME (1) ME02593B (pl)
PL (1) PL2555775T3 (pl)
PT (1) PT2555775T (pl)
RS (1) RS55617B1 (pl)
SI (1) SI2555775T1 (pl)
SM (2) SMT201700019T1 (pl)
WO (1) WO2011116290A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2424546B1 (en) * 2009-05-01 2015-10-28 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans
LT2523669T (lt) * 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
CA2792266A1 (en) * 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using n6-cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
PL2807178T3 (pl) 2012-01-26 2017-12-29 Inotek Pharmaceuticals Corporation Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
WO2014152723A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
AU2015358576A1 (en) * 2014-12-03 2017-06-22 Inotek Pharmaceuticals Corporation Methods of preventing, reducing or treating macular degeneration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423144B2 (en) * 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
CN101010085B (zh) * 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
EA015683B1 (ru) * 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
EP2424546B1 (en) * 2009-05-01 2015-10-28 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans

Also Published As

Publication number Publication date
SMT201700019B (it) 2017-03-08
ME02593B (me) 2017-06-20
WO2011116290A1 (en) 2011-09-22
ES2613254T3 (es) 2017-05-23
HUE031529T2 (en) 2017-07-28
CN102933220A (zh) 2013-02-13
EP2555775A4 (en) 2013-08-28
JP2013522322A (ja) 2013-06-13
US20110245193A1 (en) 2011-10-06
EP2555775B1 (en) 2016-12-07
DK2555775T3 (en) 2017-02-06
SI2555775T1 (sl) 2017-05-31
SMT201700019T1 (it) 2017-03-08
PT2555775T (pt) 2017-02-01
US8440639B2 (en) 2013-05-14
EP2555775A1 (en) 2013-02-13
LT2555775T (lt) 2017-04-25
HRP20170008T1 (hr) 2017-03-10
RS55617B1 (sr) 2017-06-30
CY1118495T1 (el) 2017-07-12

Similar Documents

Publication Publication Date Title
ZA201206223B (en) Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
EP2539348A4 (en) CEPHALOSPORIN DERIVATIVES AS BETA LACTAMASE HEMMER AND COMPOSITIONS THEREFOR AND METHOD FOR THEIR USE
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
ZA201401117B (en) Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
IL214226A (en) Inhibitors of beta-secretase and various related aspects thereof
ZA201207856B (en) Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2
IL253911A0 (en) Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
ZA201206257B (en) N-(imidazopyrimidin-7yl)-heteroarylamide derivatives and their use as pde10a inhibitors
IL210843A0 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL225672A0 (en) Methods and compositions for polymerase inhibition
IL230705A0 (en) Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL232977B (en) Intra-episode dexmedetomidine preparations and methods of using them
IL208403A0 (en) Compositions and use of epas1 inhibitors
ZA201206456B (en) Uses of dgati inhibitors
ZA201007129B (en) Limk2 inhibitors,compositions comprising them,and methods of their use
PL2555775T3 (pl) Kompozycje połączenia agonistów receptora adenozyny A&lt;sub&gt;1&lt;/sub&gt; i inhibitorów anhydrazy węglanowej do obniżania ciśnienia wewnątrzgałkowego
SG10201509539UA (en) Methods And Compositions For Inhibition Of Treg Cells
ZA201207688B (en) Compositions and methods for non-toxic delivery of antiprogestins
ZA201303855B (en) Benzoxazepines as inhibitors of p13k/m tor and methods of their use and manufacture
EP2381950A4 (en) COMPOSITIONS AND METHOD FOR THEIR USE
GB0907120D0 (en) Inhibitors of IKK-ß serine-threonine protein kinase
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
HK1191056A (en) Compositions and methods of use for determination of he4a
HK1192727A (en) Combination of kanase inhibitors and uses thereof
GB201012144D0 (en) P13K inhibitors and uses thereof